TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00573053

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen saturation range
Description: Maintain functional oxygen saturation range between 91 and 95%

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation range
Description: Maintain functional arterial oxygen saturations in the range of 85- 89%
Study: NCT02387190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telenursing monitoring
Description: The telenursing program protocol is based on:~1. Contact the patient by telephone, weekly;~2. Distribution and explanation of the educational booklet;~3. Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support.
Study: NCT01241825

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trident sugarless chewing gum.
Description: Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: One control group (these do not chew gum).
Description: The control group will not chew chewing gum while undergoing capsule endoscopy
Study: NCT01109680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane
Description: Multiple dose Neramexane followed by single dose 14C Neramexane
Study: NCT03055429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full Scale Unit
Description: Pre-test, usability, post-test
Study: NCT02790827

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CETA
Description: CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
Study: NCT04346459

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through Fastrach - Group A
Description: Insertion of the intubating laryngeal mask Fastrach and blind tracheal intubation through the device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through I-gel - Group B
Description: Insertion of the supraglottic airway device i-gel and tracheal intubation through the device guided by a fiberoptic bronchoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation through Protector - Group C
Description: Insertion of the laryngeal mask Protector and tracheal intubation through the device guided by a fiberoptic bronchoscope
Study: NCT02318459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity interval training-HIIT
Description: HIIT 4 times a week, 30 minutes duration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditionnal group rehabilitation
Description: Traditionnal group rehabilitation, 3 times a week, 1 hour duration
Study: NCT02585453

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Systane Gel Drops
Description: Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
Study: NCT03391817

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation administered in gastroscopy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation
Description: Fecal microbiota transplantation administered in gastroscopy
Study: NCT03921385

Intervention type: DEVICE
Intervention: Augmented Reality Headset
Description: Patients undergoing navigated cranial or spine procedures will acquire standard of care clinical high-resolution imaging to be used for registration purposes intraoperatively. VGA output on the navigation machine will be utilized to project imaging information to the augmented reality headset. The holographic image will then be recorded to assess feasibility and ease of use.
Study: NCT02473705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil and Bicarbonate
Description: 1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil and Bicarbonate Placebo
Description: 1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil Placebo and Bicarbonate
Description: Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil Placebo and Bicarbonate Placebo
Description: Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
Study: NCT01022112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-Low
Description: TA-7284-Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-Low-middle
Description: TA-7284-Low-middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-High-middle
Description: TA-7284-High-middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TA-7284-High
Description: TA-7284-High

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05031715

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine Phytosome
Description: 2 tablets of 550 mg per day (1 before lunch and 1 before dinner)
Study: NCT00635128

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-Polio
Description: A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix-Polio
Description: A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
Study: NCT03330626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InBody group
Description: As one of representative BIVA, it provides the patients' fluid status with more objective data such as TBW, ECW, ICW, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IO group
Description: Fluid removal are guided by intake-output balance.
Study: NCT05196490

Intervention type: DEVICE
Intervention: Micro-CT
Description: Micro computed tomography (micro-CT) is an imaging method in which cross-sectional images are obtained and these images are transferred to the computer through specific software, processed and stored.

Intervention type: DEVICE
Intervention: CAD/CAM
Description: CAD/CAM (computer aided design-computer aided manufacturing) is a production method that is frequently used in many areas of technology. These systems are composed of a data acquisition unit, software for designing virtual restoration, and a computerized milling device.
Study: NCT00762775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and vitamin D supplementation
Description: Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
Study: NCT01743989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Participants received a daily oral nilotinib dose of 300 mg BID, given as two 150 mg capsules BID.
Study: NCT04323540

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-implantitis reconstructive surgery
Description: For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-implantitis reconstructive surgery
Description: For both arms (excluding the already included information): defect debridement, removal of debris using titanium curettes, titanium brushes on the implant surface, irrigation with saline, application of sterile cotton pellets with saline solution. Grafting with (experimental) xenograft and soft tissue, or xenograft alone (control). Suture.~Specific to control group (active comparator): the peri-implant defect will be filled with xenograft, and a collagen membrane will be fitted and trimmed to the defect area.~Specific to test/experimental group: same as above (for control). In addition a soft tissue graft will be harvested from the palate and sutured to the buccal flap. The entire flap will then be sutured to the lingual flap.
Study: NCT01807000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiolabeled Prucalopride Succinate
Description: A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
Study: NCT03410498

Intervention type: OTHER
Group type: OTHER
Intervention: Incremental shuttle walk test
Description: In the incremental shuttle walk test, participants will have to walk between two cones (10m distance) several times. The time they will have to cover the distance between the two cones (signified by 'bleeps') will become increasingly shorter, until they cannot get to the next cone before the next 'bleep'. This test will last a maximum of 20 minutes.~In the Stroop test, the words of four colours, but written with a different colour, will be projected on the wall in front of participants and they will need to identify the colour of the text and ignore the word itself.
Study: NCT02215525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA
Description: device uses UVA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Herbal
Description: Herbal tablets, 1000 mg every 6 hours daily for 6 months
Study: NCT01741103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: sitagliptin 100mg by mouth once a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one by mouth daily for 12 weeks
Study: NCT01169922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION
Description: 2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: INFORMATION-ONLY SEXUAL RISK REDUCTION
Description: 1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
Study: NCT03636191

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic strain
Description: Lactobacillus

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01060839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single session counseling
Description: For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
Study: NCT01453400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
Description: Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen + placebo
Description: Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
Study: NCT01805752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-shifting to lower-cadre providers at PMTCT sites

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POC CD4+ cell count testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: integrated mother-infant care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prominent role for influential family members (male partners) in collaboration with CHWs
Study: NCT00854893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
Study: NCT04536038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-out
Description: A study coordinator will call the patient unless they opt-out. See arm description for more details.
Study: NCT03703167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Oral ibrutinib will be given between days 1 and 28 of each 28-day cycle and will be continued daily after completion of rituximab and lenalidomide. The starting dose of ibrutinib is 560 mg/day (dose level 1) and (dose level 2 ibrutinib: 840 mg daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral lenalidomide will be given between days 1 and 21 of each 28-day cycle for a maximum of 12 cycles. The starting dose of lenalidomide is 10 mg/day (dose level 1 \& 2) lenalidomide: 15 mg daily (dose level 3) and lenalidomide: 20 mg daily (dose level 4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous rituximab (500mg/m2) will be given on day 1 of all cycles (+/- 3 days), for up to 6 cycles.
Study: NCT04408053

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Preventive fixation of the contralateral femoral neck (Stryker Trauma and Depuy Synthes screws)
Description: 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
Study: NCT01525238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet, Oral, 2.5 mg, Single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet, Oral, 5 mg, Single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablet, Oral, 10 mg, Single-dose
Study: NCT02651532

Intervention type: DEVICE
Intervention: Confocal Laser Endomicroscopy
Description: During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)

Intervention type: DEVICE
Intervention: Confocal Laser Endomicroscopy
Description: During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
Study: NCT04637269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-BCMA CAR-T
Description: 5×10\^7 /KG 15×10\^7 /KG 45×10\^7/KG Treatment follows a lymphodepletion, chemotherapy regimen that consists of Fludarabine (30 mg/m2 per day) and Cyclophosphamide (300mg/m2 per day) for 3 days prior to cell infusion.
Study: NCT00734292

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: ● Period 1 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 2 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 3 Treatment Regimen C: placebo~SKP placebo; (two actuations)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: ● Period 1 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)~● Period 2 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 3 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: fluticasone propionate, formoterol fumarate
Description: ● Period 1 Treatment Regimen C: placebo~SKP placebo; (two actuations)~● Period 2 Treatment Regimen A: FlutiForm 250/10 ug~FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)~● Period 3 Treatment Regimen B: FlutiForm 100/10 ug~FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
Study: NCT02864069

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Description: The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training Intervention
Description: In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Intervention
Description: The combined condition will concurrently follow both the walking and the CT programs as described above.